Articles tagged with Metastasis
A phase III study found that selpercatinib significantly improves cancer progression-free survival in patients with NSCLC and RET gene translocations. The therapy also demonstrated efficacy in treating intracranial lesions, a common challenge in advanced NSCLC.
A risk model based on routine blood work can identify cancer patients who are more likely to benefit from immune checkpoint inhibitors, increasing treatment efficacy and cost-effectiveness. The study found that patients in the low-risk group had a higher response rate and longer overall survival compared to those in the high-risk group.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
A Stanford University study reveals that ENPP1 is produced by both cancer cells and healthy cells around tumors, with high levels linked to immunotherapy resistance and metastases. Researchers found that targeting ENPP1 could improve patient responses to existing medicines and help clinicians better predict patient outcomes
Cancer-associated fibroblasts in the brain secrete fucosylated poliovirus receptor that stimulates breast cancer migration and invasion. The researchers hope these findings will help develop better diagnostic and therapeutic approaches for breast cancer brain metastasis patients.
A Phase IIa international study found that a combination of zanidatamab, palbociclib, and fulvestrant improved progression-free survival by 12 months with durable responses. The treatment regimen is being developed for heavily pretreated patients with HER2+/HR+ metastatic breast cancer.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
A new study found that a type of white blood cell called tumour-associated macrophages can promote the formation of lymphatic vessels, facilitating cancer cell transport to other organs. However, these cells also reduce breast cancer spread to the lungs while increasing it to the lymph nodes.
Researchers discovered that Osteopontin induces mitochondrial biogenesis in deadherent breast tumor cells, which aids metastatic success. The study suggests a possible mechanism and targets for treating cancer metastasis by increasing ATP levels and mitochondrial mass.
Adding immunotherapy atezolizumab to chemotherapy and bevacizumab improved overall survival by 32.1 months compared to 22.8 months with standard therapy alone. The two-year survival rate was also higher, with 60% in patients treated with the experimental combination.
A systematic review of papers found abnormalities in brain cancer and potential treatment with licensed drugs. Genetic differences were discovered between smokers and non-smokers, suggesting personalized medicine approaches.
Moffitt researchers found that HDAC8 inhibition of EP300 leads to melanoma cell metastasis to the brain, while no significant impact on other organs was observed. This study provides evidence for a new therapeutic target to inhibit brain metastasis.
Researchers found that carboxylic nanodiamonds blocked melanoma cells' ability to migrate and invade across membranes. Mice treated with these nanoparticles showed reduced or no tumor metastasis compared to untreated mice.
Researchers at Duke University have developed a new computational model called Adaptive Physics Refinement (APR) that can simulate the movement of individual cancer cells across long distances within the entire human body. This approach captures detailed cellular interactions and their effects on cellular trajectory, providing valuable...
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
Researchers are exploring new ways to fight metastasis, including the use of bacteria to activate a defensive response against cancer. Stress and changes in circadian rhythms have also been linked to metastasis, suggesting that these factors may be targets for prevention or treatment.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
Researchers at IRB Barcelona have identified the mechanism by which the MAF protein promotes breast cancer metastasis, revealing a key interaction with the estrogen receptor. This finding opens up new therapeutic options for patients with high MAF levels, who may benefit from treatments aimed at preventing metastases.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
Researchers found that a specific gene, MDA-9, initiates a cellular chain reaction sparking prostate cancer metastasis. The study's findings hold significant implications for treating prostate cancer and other forms of disease.
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
Researchers found that FAAH inhibition reduced breast cancer growth in immunodeficient mice and induced apoptosis of breast cancer cells. The combination of FAAH inhibitors and endocannabinoids was the most effective treatment approach.
A multi-institutional study found that immune checkpoint inhibition and single fraction stereotactic radiosurgery does not increase the risk of radiation necrosis in patients with brain metastases from non-small cell lung cancer. The study suggests that treatment with immune checkpoint inhibitors can continue when radiation necrosis oc...
A collaborative study has developed an agarose spot migration assay to examine the ability of extracellular vesicles to attract other cells in a controlled environment. The assay revealed differences in EVs' recruitment capability for endothelial cells, particularly in highly metastatic cancer cells.
A pioneering collection of brain metastasis living samples has been established, enabling researchers to study the response to specific drugs and identify the best therapeutic options for each patient. The RENACER network connects hospitals and patients, facilitating the rapid sharing of research findings and clinical trial data.
Researchers from the Max Planck Research Group aim to investigate the local immune system of the liver to develop new immunotherapy strategies for metastatic diseases. They will examine tissue and tumor samples using state-of-the-art techniques to identify key molecules and checkpoints in complex cellular interaction networks.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
Engineers developed a nanoparticle vaccine targeting S100A9, a protein that attracts cancer cells to the lungs. The vaccine significantly reduced lung tumor growth and improved survival rates in mice with metastatic breast cancer after surgery.
A new study published in JNCCN found that intensive local-regional treatment to remove as much tumor as possible did not significantly impact overall quality of life for patients with metastatic colorectal cancer. However, the treatment was associated with a higher risk of adverse events.
A team of researchers at Mays Cancer Center has identified protein markers that could signal the early development of metastatic lung cancer. These markers have led to a $1.6 million grant and will pave the way for a clinical trial in patients with advanced lung cancer.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
Researchers at MedUni Vienna discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of P-glycoprotein, opening new possibilities for delaying relapse. This breakthrough could represent a step forward in treating aggressive triple-negative breast cancer, which has limited treatment options and ...
Scientists from IRB Barcelona have revealed how chromosomal instability activates a signalling pathway known as JAK/STAT, promoting caspase activity and DNA injury. This damage allows cells to escape from the primary tumour, thereby leading to metastasis.
Researchers at Weill Cornell Medicine discovered a distinct type of stem cell that secretes protein MFGE8, favoring tumor metastases to the spine. This finding helps explain why solid tumors often spread to the spine and could lead to new orthopedic and cancer treatments.
Researchers discuss new drugs available for HER2-positive breast cancer patients with brain metastasis, showing improved outcomes and quality of life. The development of targeted therapies has led to better survival rates among these patients.
Researchers developed nanoparticles that accumulate in cancer cells and eliminate them after photoactivation, also labeling immune cells to target similar cells throughout the body. This technology has shown promise in treating mice with implanted human tumor cells and could lead to a new treatment approach for metastatic cancers.
Researchers from Shinshu University identified citrullination as a key mechanism in lung cancer metastasis. A novel CitFbg peptide was developed to block metastatic cell homing and reduce the risk of cancer spread.
Researchers found that patients with HPV-positive cancers develop recurrent disease significantly later than those that were HPV-negative, and also are more likely to spread to the lungs. A new, highly sensitive blood test has been developed to detect cancer earlier, using a framework for combining routine blood testing and imaging.
Researchers discovered that a small subpopulation of AIB1-expressing cells in breast cancer enables invasion and metastasis. The study suggests that these subpopulations play a crucial role in tumor growth and spreading to distant sites.
Researchers discovered that immune cells create local gradients by consuming chemokines, guiding their movement and enhancing directional movement in complex environments. This finding increases understanding of coordinated immune responses and may reveal new strategies for targeting cancer
Researchers found that tumors with metastasis to the brain respond better to immunotherapy due to effective priming outside the brain. Glioblastoma, an aggressive brain cancer, does not respond well due to impaired priming step.
Researchers found that antioxidants activate a mechanism forming new blood vessels in tumor cells, which can help them grow and spread. The study suggests that dietary supplements containing antioxidants may accelerate tumour growth and metastasis in cancer patients.
A pioneering study published in Cancer Cell finds that brain metastasis alters the brain's chemistry and disrupts neuronal communication. Researchers discovered a molecule, EGR1, that may play a role in this process, paving the way for potential drug development to alleviate neurocognitive effects.
Researchers identified common bladder cancer-related mutations across species, including TP53, FAT1, and NRAS in cats, and ARID1A and KDM6A in dogs. This study provides insights into human MIBC and aids understanding of bladder cancer biology across species.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Researchers have identified a neoplastic fusion transcript RAD51AP1-DYRK4 in luminal B breast cancer, associated with higher ki67 expression and aggressive clinical characteristics. MEK inhibitor trametinib may be effective in blocking the MEK-ERK signaling driven by this fusion.
RAGE signaling maintains mesenchymal state of TNBC cells by enforcing SNAIL1 protein expression, promoting tumor cell proliferation and invasion. Inhibiting RAGE with a pharmacological antagonist reduces tumor cell plasticity and improves survival in xenograft mouse models.
Researchers identified a mechanism regulating tumor growth in the skeleton, which decreases with age and can result from hormonal changes or chemotherapy. Mineralization of bone matrix reduces tumor cell growth and promotes genes associated with better patient prognosis.
A study published in JAMA Network Open found that providing equal access to healthcare reduces disparities in treatment outcomes between Black and white patients with advanced prostate cancer. The research suggests that addressing racial disparities in healthcare may improve survival rates for this patient group.
A study by Cold Spring Harbor Laboratory researchers found that breast cancer cells trick the immune system using a molecule called MHC-II, allowing them to spread faster and evade treatment. Targeting this molecule may lead to new therapeutics and improve patient outcomes.
A new study reveals that the cellular chaperone protein GRP78 migrates to the nucleus under stress and alters gene activities, allowing cancer cells to become more mobile and invasive. This discovery offers potential new approaches for cancer treatment, including down-regulating GRP78 activity or preventing it from binding to ID2.
Researchers develop a new technique to detect circulating tumor cells in blood, overcoming noise issues with existing methods. The dual-ratio approach enhances penetration range and accuracy, paving the way for quicker diagnosis of metastasis.
Researchers have created a biomedical compound that can block the interaction of metastasis-inducing protein S100A4 with its target inside the cell. The compound inhibits properties associated with metastasis at very low doses, showing potential therapeutic role in breast cancer treatment.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
Researchers have discovered a mechanism leading to resistance in luminal breast cancer and propose using the approved osteoporosis drug denosumab to block RANK protein, promoting effectiveness of CDK4/6 inhibitors. This could lead to new treatment options for patients with metastatic breast cancer.
A new study led by Sandra Casimiro and Luís Costa found a promising molecular target, the RANK signaling pathway, that could be used in combination with standard care to avoid resistance to treatment in metastatic breast cancer. High levels of RANK in cancer cells are associated with resistance to treatment with CDK4/6 inhibitors.
Researchers discovered a novel peptide, T14, that is detectable in human keratinocytes and inversely related to age, with higher levels found in chronically photosensitive individuals. The study suggests that monitoring T14 levels may offer insights into the link between degenerative diseases and epidermal cell profiles.
Inflammatory breast cancer is a rare and aggressive form of breast cancer with poor outcomes. Research highlights the role of ERβ as a mediator of estrogen signaling, demonstrating its tumor suppressive effects in preclinical models. ERβ's antimetastatic activity may hold promise for improving treatment options for IBC.